M&A Momentum Builds as Global Deal Kickoffs Rise 31% in 1H26, Datasite Data Shows

Datasite reports global M&A “deal kickoffs” rose 31% in 1H26 vs. 1H25, suggesting stronger announced deal activity later in 2026/early 2027. Preparation time fell to a 12-day median from 14 days YoY (diligence time unchanged at 181 days), supported by AI/automation, while completion rates remained steady (global 45%). The rebound is broad-based—Americas +52% and sector momentum beyond tech (Healthcare +32%, Industrials +25%, Energy & Power +25%)—with corporate users up 28% and PE users up 23% as strategic buyers become more active.

Analysis

The signal is more useful for fee pool direction than for broad risk appetite. A faster pipeline usually feeds through first to advisory and diligence-related revenue, then only later to announced volume; the current setup favors firms with high share in sponsor-led and cross-border execution, while leaving acquirers exposed if financing costs or antitrust scrutiny keep stretching timelines. The broadening into healthcare, industrials, and energy suggests this is less a speculative tech rebound than a normalization of corporate restructuring and asset rationalization, which is typically better for bankers than for target-stock multiples.

Second-order, this should benefit independent advisors and alternative-asset platforms more than universal banks because they monetize process intensity, not just balance-sheet usage. Private equity is a mixed winner: more launches help portfolio exits and buy-side sourcing, but steady diligence length means exit windows still depend on credit spreads and equity vol, so sponsor deployment can lag the headline pipeline by 1-2 quarters. If high-yield spreads widen materially or the VIX resets above a stress threshold, this “recovery” can stay trapped in prep mode and never convert into closes.

Contrarian take: the market may overread AI/automation as a volume catalyst when it is really a cost-efficiency story. Faster prep compresses the work content per deal, which can cap incremental revenue per transaction even if counts improve; the better trade is on firms with operating leverage to higher mandate counts, not on broad market beta. The thesis weakens if advisory guidance for Q3/Q4 fails to inflect or if announced deal value does not follow kickoff momentum by year-end.

Key Decisions for Investors

• Long EVR / LAZ basket on pullbacks over the next 1-3 months; these names have the cleanest operating leverage to a rebound in announced deal volume. Risk/reward: 15-25% upside if M&A guidance inflects, but cut if 3Q fees do not improve or if risk assets sell off sharply.
• Long BX or KKR as a 6-12 month proxy for higher sponsor activity and exit optionality. Prefer buying on weakness, because the thesis is fee growth rather than immediate realizations; invalidate if credit spreads widen enough to choke sponsor underwriting.
• Pair trade: long advisory-heavy financials vs short a diversified bank basket (e.g., EVR/LAZ vs BAC/C) for 3-6 months. The spread should work if deal conversion improves without a broad loan-growth rebound; exit if underwriting/IB fee guidance does not outperform.
• Set a watch alert on HY spreads and VIX rather than forcing an equity trade: if HYG OAS widens >75 bps from current levels or VIX stays >20 for two weeks, reduce exposure to M&A beneficiaries because kickoff data will likely fail to convert into closes.